Interest in bronchiectasis has increased over the past two decades, as shown by the establishment of diseasespecific registries in several countries, the publication of management guidelines and a growing number of clinical trials to address evidence gaps for treatment decisions. This review considers the evidence for defining and treating pulmonary exacerbations, the approaches for eradication of newly identified airway pathogens and the methods to prevent exacerbations through long-term treatments from a pragmatic practice-based perspective. Areas for future studies are also explored.
INTRODUCTION
There has been increasing interest in the field of bronchiectasis over the past two decades. The term orphan disease should now be considered redundant for this condition. [1] [2] [3] Many studies have reported increasing prevalence, particularly in indigenous populations, and have highlighted the limited evidence base for therapeutic decision-making. 4, 5 Bronchiectasis-specific registries have been launched in the past 10 years including the EMBARC European Bronchiectasis Registry 6 (https:// www.bronchiectasis.eu/registry), the US Bronchiectasis Research Registry 7, 8 (https://www.copdfoundation.org/ Research/Bronchiectasis-Research-Registry/Learn-More. aspx) and the Australian Bronchiectasis Registry (https:// lungfoundation.com.au/health-professionals/bronchiect asis-registry/, accessed 20 July 2018) established to enhance understanding of the demographics, risk factors, natural history and impact on health-related quality of life (HRQoL).
Initial reports from the European and US registries were published in the past 2 years [6] [7] [8] and these registries are now combined to form an alliance, the International Bronchiectasis Network. They have already provided an opportunity for patients with bronchiectasis to be identified as potential participants in clinical trials to obtain stronger evidence for bronchiectasis management.
Until such evidence is available, clinicians are reliant on guidelines to support clinical decision-making. The first national guideline from the UK was published in 2010, with now a number of national and one international guideline published; from Spain (initially in 2008 and revised in 2018); from Australia and New Zealand (initially 2010, revised 2015, indigenous guideline 2008); from Saudi Arabia (2017); and the European Guidelines (2017). [9] [10] [11] [12] [13] [14] [15] [16] Of note the strength of evidence to support decision-making is limited for most recommendations within these guidelines. 15 Further research in all areas is urgently required. However, it is concerning that many recent clinical trials particularly of inhaled antibiotics have not achieved their primary endpoint(s). [17] [18] [19] [20] This may in part relate to several factors including the aetiology of bronchiectasis being heterogeneous, varying disease severity and age of presentation ranging from young children to the elderly. The impact of therapeutic interventions may differ amongst those with bronchiectasis from different causes.
Using the search terms 'bronchiectasis' and 'clinical trials' (PubMed), 53 Chronic airway infection is routinely described (particularly with common pathogens including Haemophilus influenzae infection and Pseudomonas aeruginosa infection) 21, 22 and pulmonary exacerbations are frequent. 23 Recent data from the EMBARC Bronchiectasis Registry has demonstrated that~50% of patients had two or more exacerbations annually and one in three required hospitalization. 23 It is well known that pulmonary exacerbations are associated with increased local airway and systemic inflammatory response and progressive disease. [24] [25] [26] [27] [28] The severity and frequency of exacerbations adversely impact daily symptoms, HRQoL, lung function decline and mortality. [29] [30] [31] [32] [33] [34] The purpose of this review is to address three specific areas in treating adults and children with bronchiectasis: 1 Definitions and management of pulmonary exacerbations; 2 Approaches to eradication of infection; 3 Long-term treatment aimed at reducing pulmonary exacerbations.
Under each of these three areas, we have proposed five questions and provide a synthesis of the evidence to support decision-making for the clinician with a patient with bronchiectasis in the clinic setting. We suggest pragmatic approaches based on the current published evidence and guidelines.
DEFINITION AND TREATMENT OF EXACERBATIONS IN BRONCHIECTASIS How important is the effect of exacerbations on outcomes?
Exacerbations of chronic lung conditions such as COPD and cystic fibrosis (CF) are linked with infection and associated with poor outcomes. 35, 36 In bronchiectasis, increased pulmonary exacerbation frequency was associated with reduced forced expiratory volume in 1 s (FEV 1 ), increased severity of lung disease on CT scan and chronic infection with P. aeruginosa and H. influenzae. High levels of sputum neutrophil elastase were also associated with exacerbations suggesting that airway inflammation may also be an important factor. 24 In studies utilizing the Bronchiectasis Severity Score 30 and the modified FACED plus exacerbations (E-FACED) score, 37 the strongest predictor of future exacerbations was previous severe exacerbations with these scores used to successfully predict future morbidity. Prior hospitalization was also an independent predictor of mortality. 30 A study to determine a 'Frequent Exacerbator Phenotype' from adults with bronchiectasis found that using 1 year as a baseline the incident rate ratio of future exacerbations over the next years was estimated at 1.73 for one exacerbation per year at baseline, 3.14 for two exacerbations and 5.97 for those with >3 exacerbations. 23 In children, longitudinal monitoring of lung function for 3-5 years following diagnosis of bronchiectasis demonstrated that while the overall cohort improved, a subgroup did not and this was associated with increased numbers of exacerbations (>2 per year). 38, 39 In other studies, an annual reduction of FEV 1 between −0.9% and −1.9% predicted over a minimum follow-up of 5 years was recorded, despite treatment, with greater reductions in those with chronic H. influenzae infection, which itself is associated with more frequent exacerbations. 40, 41 In CF and primary ciliary dyskinaesia, single exacerbation events are associated with a failure to return to their baseline FEV 1 by 3 months in~25% of children. [42] [43] [44] In children with bronchiectasis, for each hospitalized exacerbation, the FEV 1 decreased by 1.95% 39 and a significant worsening in parent-specific HRQoL scores. 45 Therefore, there is a reasonable evidence base that treatment and, even more importantly, prevention of exacerbations will improve short-and long-term health outcomes in this population.
What is an exacerbation? Do definitions help?
While exacerbations are considered to occur with a change in, or development of new, symptoms, a standard definition has been difficult to ascertain with some studies giving weight to differing parameters, or major and minor criteria, with the majority also requiring that the episode received antibiotic treatment. A recent systematic review identified 50 trials with 20 different definitions. 46 This international consensus of experienced clinicians proposed that the definition includes: (i) a deterioration in three or more of the following key symptoms for at least 48 h: cough; sputum volume and/or consistency; sputum purulence; breathlessness and/or exercise tolerance; fatigue and/or malaise; haemoptysis and (ii) a clinician determines that a change in bronchiectasis treatment is required. While this definition will be of value in clinical practice, the authors emphasize that it is a definition for research with a likely high specificity and with a bias towards more severe exacerbations. Individual patients may not reach these criteria or have additional symptoms not detailed within the definition but would still be considered to have an exacerbation requiring treatment.
Notably, measurements of lung function were not included in the definition as they are rarely helpful in confirming an episode of exacerbation in patients with bronchiectasis. In the consensus process, neither laboratory findings nor chest X-ray changes reached a sufficient threshold of support to be included. 46 It is recognized that the 'change of treatment' will most likely be the initiation of antibiotics (oral, systemic or inhaled), but other possible changes could be the commencement of oral corticosteroids, mucolytics or change in airway clearance technique.
Generally, clinical trials in children have adopted similar definitions as for adults, 47 although haemoptysis is rare and productive sounding (wet) cough is more common than sputum production. A review of 81 exacerbations in children with the purpose of defining an episode reported that wet cough or cough severity (score ≥ 2) were the best predictors. Sputum colour, dyspnoea, haemoptysis, new clinical signs on chest examination or chest pain were considered minor criteria. The addition of particular laboratory measures (C-reactive protein (CRP), amyloid and IL6) improved the specificity and the positive predictive value of the definition-but these are not readily clinically available. 48 Currently, there are no laboratory biomarkers that have been validated for bronchiectasis and how best to assess clinical status and response to treatment is poorly understood. Many clinicians managing adults with bronchiectasis use CRP as a measure of systemic inflammatory response to support decision-making on whether to initiate antibiotics and as a marker of treatment response in patients with bronchiectasis. Potential biomarkers of promise in the research setting include high-sensitivity CRP, 49 neutrophil elastase 24 and various pro-inflammatory cytokines. 28, 50, 51 What are the optimal drugs, doses and duration? When should i.v. antibiotics be used?
It is a usual practice to initiate antibiotic treatment with some knowledge of the likely organism causing symptoms at that time. In the majority of patients with bronchiectasis,. this will be H. influenzae, Moraxella catarrhalis or P. aeruginosa. Staphylococcus aureus or methicillin-resistant S. aureus (MRSA) can also be present although there is less certainty as to the impact these organisms have. 52 Non-tuberculosis mycobacterium (NTM) is also increasingly described in 5-10% of patients whether because of increased awareness, increased surveillance or a true increase. 53, 54 In children, the most common infecting organisms are H. influenza, M. catarrhalis and Streptococcus pneumoniae. P. aeruginosa is much less common and seen predominantly in older children with severe disease, or younger children with co-morbidities of aspiration, or who have long-term tracheostomies. 48, 55 While the types of organisms found worldwide are similar, exact prevalence can vary according to age, region, ethnicity, referral centre, underlying cause of bronchiectasis, clinical state and recent antibiotic use. 4, 21, 52 There will also be variation depending on sample site, sample adequacy and culture methods. Information on the current infecting organism will usually not be available until sputum culture and organisms are identified which will be 3-5 days after the sample has been processed. A knowledge of prior microorganisms is therefore very helpful in making a decision on which antibiotic is likely to be most useful. Regular sputum culture when patients are stable is therefore valuable.
Sequencing the 16S ribosomal RNA genes in adults revealed greater bacterial diversity within sputum than detected by culture. 56, 57 In a study of the respiratory microbiome in children, the profile of those with CF, protracted bacterial bronchitis or bronchiectasis had more similarity between these groups than when compared to adults with CF or bronchiectasis. 58 However, at this stage, airway microbiota determination is a research rather than a clinical tool.
The guidelines suggest empirical antibiotic choices predominantly divided into whether directed against P. aeruginosa or other organisms. [10] [11] [12] [13] [14] [15] Most exacerbations can be managed with oral antibiotics but if symptoms are moderate/severe or repeated oral therapy has not led to resolution or the individual is physiologically compromised or has co-morbidities, then an intravenous (i.v.) course of antibiotics may be warranted. For P. aeruginosa, oral oxyquinolone (ciprofloxacin) is the recommendation with a beta-lactam antibiotic (e.g. ceftazidime) with or without tobramycin indicated for i.v. treatment amoxycillin-clavulanic acid, doxycycline (>8 years old), oral second-generation cephalosporins and sulphamethoxazole/trimethoprim will cover H. influenzae and M. catarrhalis. Where S. aureus is likely to be the predominant pathogen, sulphamethoxazole/trimethoprim or doxycycline may be effective as these antibiotics usually have anti-MRSA activity (depending on the local susceptibility patterns). For i.v. treatment, usually a broad-spectrum antibiotic such as a third-generation cephalosporin is used. Antibiotic therapy should be in line with local guidelines for respiratory infection and discussed with the infection team if deviations from local guidelines are required.
The duration of either oral or i.v. antibiotics has not been systematically studied in bronchiectasis. The practice of using 14 days has been extrapolated from CF practice, without definitive evidence in this population either, and is recommended in the guidelines. 10, 11, 13, 14 The European Respiratory Society (ERS) guidelines systematically reviewed the literature comparing shorter (<14 days) versus longer (14-21 days) treatment. 15 In one study only, outcomes were similar at 7 and 14 days. 59 However, as most studies had used 14 days and shown good outcomes, in the face of lack of evidence to the contrary, this remained the recommendation in this guideline. There are currently studies underway in patients with CF to determine the optimal length of treatment and similar studies may be valuable in bronchiectasis.
What non-antibiotic therapies should be considered for exacerbations?
There are no systematic studies to determine if adjunctive therapies are important in treating exacerbations.
Airway clearance
A regular programme of airway clearance has been associated with reduced symptoms of cough and improved quality of life (QoL) 60, 61 and proven more effective than no treatment. 62 Only one study compared techniques during acute exacerbations 60 ; however, chest physiotherapy by different techniques led to improvement in cough-related HRQoL even when used for a short period. 60 As most exacerbations are associated with an increase in cough and sputum, it is plausible that an increase in the frequency and perhaps change of technique of airways clearance may benefit.
Corticosteroids
In patients admitted to hospital with an exacerbation of bronchiectasis, the use of systemic steroids was associated with a threefold increased risk of mortality. 63 A recent review determined no studies on the use of inhaled corticosteroids with acute exacerbations. 64 However, a small study in children looked at withdrawing inhaled corticosteroids over 12 weeks resulting in increased bronchial hyper-reactivity and a decrease in neutrophil apoptosis but no change in sputum inflammatory markers. 65 In adults, inhaled corticosteroids did improve HRQoL and reduce symptoms in those in 'steady-state' bronchiectasis. 66 The appropriate use of steroids in bronchiectasis is complicated by the overlap of COPD and asthma in a significant number of patients.
Mucolytics. Only one study compared the mucolytic bromhexine against placebo showing that it improved ability to expectorate mucus during an exacerbation. 67 No other studies have looked at use during exacerbations. Single doses of nebulized hypertonic saline increased expectorated sputum weight. 68 Studies comparing hypertonic saline with normal saline have conflicting results and all are during time of usual care. Inhaled mannitol has been shown to be effective in prolonging time to first exacerbation and improving HRQoL but again not studied specifically during an exacerbation. 69 Other. Exacerbations are frequently associated with weight loss and attention should be given to energy intake. In adults, particularly older patients, other comorbidities may also be important to consider and drug side effects and drug-drug interactions should be considered.
What do you do if the patient is not improving?
Failure to respond to antibiotic therapy for a pulmonary exacerbation may be due to a number of factors including exacerbations caused by viral infections, fungal airway complications and other medical comorbidities and coexistent psychosocial stressors, anxiety and depression. These factors should be considered in the patient who is responding suboptimally to therapy.
Changing antibiotics is a frequent response when there is a failure to improve and can be modified once susceptibility profiles are known, although in vitro antibiotic susceptibility testing does not always predict therapeutic outcome. 70 One study added inhaled tobramycin to 2 weeks of oral ciprofloxacin during acute treatment but while this reduced bacterial load it did not lead to improved clinical outcomes and lead to emergent wheeze in 50% of participants. 59 New bacterial pathogens should be looked for and in children the difficulty of getting adequate lower airway samples means a bronchoalveolar lavage may be needed. In more severe patients, a failed response may be associated with a raised CRP and white cell count. In addition, viruses have been identified in 49% of adults at the time of exacerbation compared to 19% when stable 71 and in 9% of patients during a winter season compared to 33% during summer. 72 Careful attention should be given to hypoxaemia and/or hypercapnia. Other causes of complications such as a pneumothorax or haemoptysis should be investigated. Co-morbidities such as coronary artery disease, cardiac failure or diabetes should have treatment optimized as these may contribute to the symptoms.
ERADICATION TREATMENT IN BRONCHIECTASIS
In the clinically stable patient with bronchiectasis, should Pseudomonas eradication at its first isolation be considered?
Published guidelines recommend antibiotic treatment of initial isolates of P. aeruginosa. 11, [13] [14] [15] 73 Whilst eradication approaches are well established in children with CF 74 and more recently adults with CF, 75 this approach is based on non-controlled, non-randomized or observational clinical studies in patients with bronchiectasis.
Four recent studies specifically address the impact of eradication of P. aeruginosa infection. The studies from centres in Spain and the UK ranged from 30 to 64 participants and involved a range of regimens and associated with eradication of~50-60% at~6-12 months after completion of therapy [76] [77] [78] [79] (Table 1) . It is however not clear from longitudinal studies how many patients spontaneously clear P. aeruginosa over time. Additionally, studies examining a range of RCT of inhaled antibiotics (tobramycin, gentamicin, ciprofloxacin; aztreonam) demonstrate eradication of P. aeruginosa as a secondary endpoint of the clinical trial [80] [81] [82] [83] [84] between~30% and 60%.
Whilst further high-quality studies are required, evidence to date supports antibiotic therapy to attempt to eradicate P. aeruginosa to avoid the development of chronic infection, although relapse rates in the first 6-12 months occur in a proportion of patients. A study from Belfast, UK, demonstrated success rates of eradication of 52% at 6 months, and of those~30% will relapse by 12 months.
What is the best regimen for P. aeruginosa eradication?
There are limited data to support the choice of regimen for P. aeruginosa eradication. No RCT have been undertaken to address this question. Guidelines vary in the recommended approaches (drug choice, duration and combinations) from oral ciprofloxacin with or without an inhaled antibiotic (tobramycin or colistin) which may be continued for up to 12 months. [13] [14] [15] The role of i.v. antibiotics is less clear but also recommended if further treatment is required. [77] [78] [79] The recently published ERS bronchiectasis guidelines provide three alternative eradication protocols, based on the published uncontrolled studies (Fig. 1) . 15 When faced with a patient with a newly identified P. aeruginosa culture, these options should be considered in parallel with current clinical status of the patient (stable vs recent decline), time since isolate initial treatment with ciprofloxacin 750 mg/12 h for 3 weeks is recommended. An inhaled antibiotic for 3 months can be added if the patient is unable to use ciprofloxacin (intolerance or allergy), where the patient has evidence of severe bronchiectasis and/or is immunosuppressed. However, in CF, inhaled treatment seems to be more important than oral ciprofloxacin for P. aeruginosa eradication. 85 If the initial P. aeruginosa isolates coincide with a pulmonary exacerbation, admission and a course of 2 weeks of i.v. antibiotics are recommended.
Options to consider if P. aeruginosa recurs within 1 year include re-treatment with ciprofloxacin and an inhaled antibiotic (same or alternative antibiotic to that prescribed in the initial therapy) or combination of i.v. antibiotics with concurrent inhaled antibiotic.
A key factor in appraising the effectiveness of therapy is sputum surveillance for clearance of P. aeruginosa (during, at completion and in follow-up).
Should eradication be considered for other bacteria (e.g. S. aureus, H. influenzae, S. pneumoniae and MRSA) and be treated in a clinically stable person with bronchiectasis?
Most evidence to date highlights that P. aeruginosa is associated with poorer clinical outcomes (e.g. increased mortality, increased pulmonary exacerbations and increased pulmonary function decline). 22, 31 Bacterial infection with non-Pseudomonal bacteria is associated with pulmonary exacerbations (both numbers and severity), 37, 86 therefore the likely impact of attempting to eradicate such infections is less clear. Chronic bacterial infection, particularly H. influenza, is associated with poorer outcomes in children with bronchiectasis. Attempted eradication in such cases may be important; however, there are no data to date to support decision-making. The systematic review examining the role of inhaled antibiotics (six trials) for patients with bronchiectasis showed no difference in the impact of P. aeruginosa eradication when compared with any bacteria. 87 One potential exception is that of managing early MRSA infection-the British Thoracic Society guidelines recommend attempted eradication of newly acquired infection for children. 14 Whilst there are no RCT to support antibiotic selection, duration or risk-benefit in bronchiectasis, rationale appears to be linked to the potential to cause healthcare-acquired infections. Further studies are required to determine the impact of eradication of non-Pseudomonal bacteria on the natural history of bronchiectasis.
Does the prescription of frequent and/or long-term antibiotics to prevent pulmonary exacerbations increase the risk of P. aeruginosa and other Gram-negative nonfermenting bacteria acquisition?
Selective pressure of broad-spectrum antibiotic use is well established. Persistent H. influenzae and P. aeruginosa are clearly associated with the frequency of pulmonary exacerbations, although data to support the intensive use of antibiotics to treat non-Pseudomonal pathogens are limited in bronchiectasis. Two non-culture microbiome studies have reported interesting results. Patients with bronchiectasis on long-term erythromycin had evidence of changes in the composition of respiratory microbiota when exposed to macrolides. Specifically, patients without P. aeruginosa infection had lower rates of H. influenzae detected and increased rates of macrolide-tolerant pathogens including P. aeruginosa. 88 However, this did not result in a change in pulmonary exacerbation rates. In another hospital-based cohort, the structure of the airway microbiota was highly specific to an individual, and was generally stable over 6 months of study despite changes in the clinical status and antibiotic usage for a individual patient. 89 Further studies of microbiological risk factors (using standard bacteriological culture and molecular microbiome studies) to better understand the impact of broad-spectrum and long-term antimicrobials on the establishment of more antibiotic resistant pathogens are needed.
How to monitor if eradication has been successful in an individual patient?
Sputum bacteriological analysis is the usual approach to identify airway pathogens. Timing and frequency of sputum culture vary in the clinical care of patients ranging from taken at each outpatient assessment, during pulmonary exacerbations or when sputum is purulent, and even annual basis only. 90 More invasive approaches (e.g. sputum induction and bronchoscopy) should be considered for the patient who is deteriorating but unable to spontaneously expectorate sputum or does not stabilize after attempted eradication.
There are no guidelines to assess efficacy of eradication therapy, although studies of the impact of antibiotics in bronchiectasis have reported pathogen eradication at the end of clinical trials (where eradication was a secondary endpoint), 91 at next clinic review, 79 at 3 and 12 months of follow-up 77 and where no Pseudomonas was cultured in three sputum samples over 6 months after eradication. 78 It would be pragmatic to assess sputum culture (at least once) at the next clinic appointment after antibiotics are completed and to assess regularly in the year following. The Spanish guidelines recommend sputum culture to be performed monthly for the first 3 months after completing initial treatment and every 2 months thereafter for 1 year. 13 A recent study has evaluated the role of anti-P. aeruginosa IgG antibodies. 77 Key results from this study demonstrated that a positive Pa-IgG antibody test had high sensitivity (95%) and moderate specificity (74%) in patients with chronic P. aeruginosa infection. In patients with new P. aeruginosa isolation, eradication therapy was administered to all patients. Notably, eradication (negative sputum) at 12 months was more commonly (89.5%) seen in patients with a negative antibody test than in patients with a positive test (15.8%), suggesting that the baseline analysis of Pa-IgG antibodies may be useful in determining the likely efficacy of eradication therapy.
LONG-TERM TREATMENTS OF BRONCHIECTASIS Should long-term or rotational antibiotics be used?
Bacterial infection (any) is associated with more frequent and more severe exacerbations. 37, 86 However, the effects are greater with P. aeruginosa infection with increased mortality (OR: 2-2.9), hospital admissions (OR: 2-6.6), exacerbations (one per year), worse lung function and poorer HRQoL (St George's Respiratory Questionnaire (SGRQ): 18.2 points lower). 22, 31 Direct correlations between bacterial load and inflammation have been demonstrated in adults 29, 92 and children. 48 Inflammatory products, such as neutrophil elastase, have also been independently associated with exacerbation frequency and lung function decline. 24 Thus, reducing both bacterial colonization and interlinked inflammation could independently affect the course of disease.
A Cochrane review of antibiotic therapy in patients with bronchiectasis included 18 trials (1157 persons, 13% children). Antibiotics administered for 4-83 weeks (inhaled or oral) against 'short term as needed' or placebo showed a significant reduction in pulmonary exacerbations (271 per 1000 in intervention compared with 546 per 1000 in controls). 93 There was also a reduction in hospitalizations (37 per 1000 in intervention compared with 87 per 1000 in controls). No significant changes in FEV 1 (reported in 88% of studies) were shown but reductions in sputum purulence and volume, systemic inflammatory markers and SGRQ were described in the studies when these were measured.
Bronchiectasis guidelines recommend long-term antibiotics for those with ≥3 exacerbations per year, with or Pulmonary exacerbations in bronchiectasis without chronic infection with P. aeruginosa, 10, 11, 14 but the more recent guideline 13 suggests use for ≥2 exacerbations in the community or one hospitalization as indications for long-term antibiotics. None of the guidelines have recommended rotational antibiotic use, although this practice is standard care in CF with inhaled antibiotics. 94 However, long-term antibiotic use has important disadvantages in particular on antimicrobial resistance as described in the Cochrane review (155 per 1000 in intervention compared with 50 per 1000 in controls). 93 The development of resistance is an inevitable consequence of taking long-term antibiotics. The evolution of resistance is also influenced by treatment adherence (better adherence-less resistance documented). 95 The current benefit-risk of improving the future course of disease versus emerging antimicrobial resistance has given rise to four recent Cochrane systematic reviews to assess the antibiotic effects in patients with bronchiectasis. [96] [97] [98] [99] What is the role of nebulized antibiotics and which is the most useful?
The place of nebulized antibiotics is well established in CF. 100, 101 To date, none have been approved or registered for the treatment of patients with bronchiectasis. 86 A number of randomized placebo-controlled trials investigating tobramycin, 19 Table 2 ). The majority involved older adults (mean age of these studies ranges from 57 to 69 years) who had chronic P. aeruginosa infection and advanced pulmonary disease. The studies varied in duration from 2 weeks (on/off for 12 cycles), 17, 18 1 month (on/off for one to six cycles) 17, 18, 80, 81, 83, 84 or  6 19,20 to 12 months 82 continuous. While there have been some clinical and/or microbiological improvement, the results compared to similar trials in CF populations have generally been less positive and inconsistent. The longer courses (6-12 months) colistin or gentamicin showed significant reductions in exacerbations (33-49% with treatment vs 59-80% with placebo) and increased time to first exacerbation (median days to exacerbation of 120 and 165 with treatment compared with 61 and 111 with placebo). 20, 82 A similar finding was reported in one of the four ciprofloxacin studies. 17, 18 Only one study using 6 months of nebulised tobramycin (TOBI; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey) reported reduction in hospitalizations (by 74%) but interestingly no difference with community exacerbation frequency. 19 In contrast to CF, only one study in bronchiectasis has described an increase in FEV 1. 82 The SGRQ improved in four of the six studies 18, 81, 82, 84 and the Quality of Life-Bronchiectasis (QOLB) questionnaire 105 improved in one aztreonam study. 18, 81 The most consistent finding has been a reduction of bacterial density, usually P. aeruginosa 20, [82] [83] [84] 104 with eradication described in 30-35% (and eradication up to 93% of other Gram-negative bacteria). 18, 80, 82, 84 Reduction in myeloperoxidase, free elastase 82 and CRP 84, 104 has been reported but not consistently 19 and such reductions were not related to clinical improvements.
There have been no published trials evaluating inhaled antibiotics in children. While P. aeruginosa infection is rare at this age, such treatment may be more efficacious given the greater potential of earlier disease stage (less structural changes), possibility of lung growth and this population being more similar in age to those in the CF studies.
An increase in adverse events with treatment has repeatedly been described, occurring more often than in CF trials-notably bronchoconstriction and wheeze often necessitating termination of treatment. 19, 20, [80] [81] [82] 102 Surprisingly, such events appear less frequently with the dry powder devices. 17, 18, 83, 84 The emergence of resistant microorganisms with a fourfold increase in minimal inhibitory concentration for P. aeruginosa occurs in 7-50% of the treated groups. 17, 18, 81, 83, 84 Three bronchiectasis guidelines recommend that patients having more than three exacerbations annually and or those chronically infected with P. aeruginosa could be considered for inhaled antibiotics with no preferred protocol given. 10, 11, 14, 15, 29 One guideline recommends use for any 'potentially pathogenic' bacteria with two exacerbations in the community or one hospitalization, and highlighting preference for inhaled antibiotics rather than systemically administered therapy. 13 There seems to be more success with longer continuous use of inhaled antibiotics, but there are significant concerns with emergence of antimicrobial resistance.
Who should receive macrolides, and which one, for how long?
Three RCT including 341 adults examining azithromycin (in two) and erythromycin (in one) for 6-12 months consistently showed a reduction in exacerbation frequency (34-66%), a doubling of median time to next exacerbation, yet a variable effect in lung function (improvement in FEV 1 of 3-4% in two studies) and QoL questionnaires (improvement in one). [106] [107] [108] In children, an RCT of weekly azithromycin for a mean duration of 20 months in 89 participants demonstrated a 50% reduction in respiratory exacerbations, and a 30% reduction in hospitalization rates (Table 3 ). In addition, there was a 50% reduction in antibiotic use (all) and a significant improvement in weight-for-age (+1.3 compared with +0.2 Z-score). 47 Azithromycin, in comparison with other macrolides, is notable for its high intracellular accumulation and its ability to prevent biofilm formation by impairing quorum sensing signals. 111 It also has a lower burden of treatment as daily, three times a week or even weekly dosing is possible. Macrolides are generally well tolerated but a major concern is evolution of antimicrobial resistance. While resistance was similar in the groups at baseline, treatment arms showed an increase (88% had resistant strain(s)) compared with placebo (26%; all isolates). 106 In one study, erythromycin resistance of Streptococci isolates was 27.7% (active) compared with 0.04% (placebo) after 12 months of therapy. 107 Similarly, after 20 months of azithromycin, there was significantly lower carriage of H. influenzae and M. catarrhalis but seven times greater risk of azithromycin-resistant bacterial carriage. 95 Adherence to antibiotics impacted rates of resistance. In patients taking ≥70% of medication, there were lower rates of any pathogens identified and fewer macrolide-resistant organisms. After 6 months of study completion without azithromycin, the macrolide resistance for S. pneumoniae declined significantly from 79% to 7%, although resistance remained high for S. aureus. A further caution is the increased risk of macrolide therapy when prescribed for any indication to cause hearing loss, tinnitus and cardiac arrhythmias (ventricular arrhythmias, torsade des pointes and prolonged QT) and sudden cardiac death. This has largely been described in the elderly and those with severe disease, significant other co-morbidities and on other QT-prolonging medication. 112, 113 A further concern is the failure to recognize non-tuberculous mycobacterial infection (NTM) in the patient with bronchiectasis prior to or emerging during macrolide therapy. Monotherapy with macrolides may increase rates of macrolideresistant NTM. Whilst one study suggested the emergence of Mycobacterium abscessus infection in adults with CF on long-term azithromycin therapy, 114 this has not been confirmed in three other studies where azithromycin was associated with reduced risk of M. abscessus. [115] [116] [117] Studies specifically in the bronchiectasis population are required to better understand the association, particularly as there is in vitro evidence that azithromycin can impair autophagic and phagosomal macrophage degradation. 114 Recent bronchiectasis guidelines recommend screening sputum in patients with bronchiectasis with a minimum of one negative NTM culture prior to commencing macrolide therapy. 10, 11, 13, 15 In his recent review, Hill recommended sputum induction or even bronchoscopy sampling should be considered in the non-sputum productive patient. 118 Guidelines recommend macrolides for those with frequent pulmonary exacerbations or chronic P. aeruginosa infection 10, 11, 14, 15 or for any chronic infection with a pathogen identified 13 for 12-24 months with adherence being critical to reduce emerging antimicrobial resistance.
What is the role of airway clearance techniques (physiotherapy, mucolytics and exercise)?
This area of management will be the basis for another review within this series and will not be covered in depth here. In summary, guidelines currently recommend regular chest physiotherapy to be tailored to the individual and regular exercise. Trials of hypertonic saline or mannitol are recommended in adult patients with difficulty in expectorating sputum and poor QoL. Dornase alpha is not recommended. 10, 11, [13] [14] [15] Are there any anti-inflammatory medications to consider in management?
There is an overlap of patients with asthma, COPD and bronchiectasis but with airway inflammation present in all and many having asthma-like symptoms, inhaled corticosteroids may be potentially useful in all. A recent Cochrane review included seven studies with 380 adults describing no significant differences from baseline in FEV 1 , average exacerbation frequency or QoL when used for 6 months or less. 64 A single study similarly showed no significant difference in FEV 1 or other clinical parameters after 12 months. One trial in 40 adults used high-dose inhaled budesonide for 3 months and then randomized to 3 months continued high-dose budesonide or medium-dose budesonide with a longacting beta-agonist. 119 The combination led to improved dyspnoea index (1.39 vs 0.1), increase in cough-free days (15.3% vs 3%) and a reduction in rescue beta-agonist inhalations required per week (−3.2 compared with −0.2) with no change in HRQoL, FEV 1 or hospitalizations. Two other small studies; one using fluticasone and salmeterol showed lung function improvement; the other using combined inhaled corticosteroid and short-acting beta-agonist reported reduced sputum and fewer days of hospitalization. 120 A number of small trials have looked at the effect of other anti-inflammatory medication in bronchiectasis achieving some reduction in inflammatory markers but without translation into significant clinical improvements. Two early studies using inhaled 121 or oral indomethacin 122 for 2-4 weeks involving less than 10 patients reported reduced sputum volume, improved the Borg Dyspnoea Scale score 121 and significantly reduced neutrophil chemotaxis and degradation products with no change in bacterial density. 122 Atorvastatin (modulates inflammation by an unknown mechanism) reduced neutrophil activation and inflammatory markers with improvements in SGRQ when used in a cross-over study for 3 months in 32 adults chronically infected with P. aeruginosa.
50 A cysteine-X-cysteine chemokine receptor-2 antagonist 'AZD5069' (to block IL8 binding and neutrophil migration) used for 4 weeks in 52 adults reduced sputum neutrophils by 69% but inflammatory markers increased and no clinical benefits were demonstrated. 123 A neutrophil elastase inhibitor 'AZD9668' used for 4 weeks in 38 adults did not change sputum neutrophil numbers but did decrease sputum inflammatory markers. 124 There has also been in vitro exploration of novel non-antibiotic macrolides with similar antiinflammatory effects as azithromycin but negligible antibiotic activity. 125 These improved human alveolar macrophage activity to phagocytose non-typeable H. influenzae and apoptotic epithelial cells with a reduction in inflammatory markers. This could be especially important for children with early disease and chronic infection with H. influenzae.
While these avenues warrant exploration, caution is advised. A double-blind RCT of a leukotriene B4 receptor antagonist in 420 individuals with CF planned for 24 weeks was stopped after an interim analysis showed increased exacerbations and more serious adverse events in the treated group. 126 The compound was subsequently shown to decrease airway neutrophils but increase P. aeruginosa numbers in CF mice. 127 Such concerns were further emphasized in a study of infliximab, used for 24 weeks in 234 patients with COPD which had no effects on designated outcomes but a trend to increased pneumonia in the treated group.
The current recommendation from guidelines is to prescribe inhaled corticosteroids for patients with bronchiectasis and a formal asthma diagnosis only. 10, 11, [13] [14] [15] Other anti-inflammatory agents are not recommended for use in bronchiectasis until more evidence is available. 10, 11, [13] [14] [15] 
CONCLUSIONS, FUTURE DIRECTIONS AND CHALLENGES
This review has emphasized that more evidence to support clinical decision-making is required, specific for patients with bronchiectasis. Despite a growth in the numbers of study reports, including new and repurposed antibiotics, mucolytic therapies and physical therapies, not all recent studies have supported the implementation of the specific therapy into the clinic. Encouragingly, the event of Bronchiectasis Registries provides an enhanced understanding of the prevalence and natural history of bronchiectasis. Several therapeutic approaches have shown significant promise. 
